Cost-related medication nonadherence in Canada: a systematic review of prevalence, predictors, and clinical impact
Tóm tắt
Cost-related nonadherence to medications (CRNA) is common in many countries and thought to be associated with adverse outcomes. The characteristics of CRNA in Canada, with its patchwork coverage of increasingly expensive medications, are unclear. Our objective in this systematic review was to summarize the literature evaluating CRNA in Canada in three domains: prevalence, predictors, and effect on clinical outcomes. We searched MEDLINE, Embase, Google Scholar, and the Cochrane Library from 1992 to December 2019 using search terms covering medication adherence, costs, and Canada. Eligible studies, without restriction on design, had to have original data on at least one of the three domains specifically for Canadian participants. Articles were identified and reviewed in duplicate. Risk of bias was assessed using design-specific tools. Twenty-six studies of varying quality (n = 483,065 Canadians) were eligible for inclusion. Sixteen studies reported on the overall prevalence of CRNA, with population-based estimates ranging from 5.1 to 10.2%. Factors predicting CRNA included high out-of-pocket spending, low income or financial flexibility, lack of drug insurance, younger age, and poorer health. A single randomized trial of free essential medications with free delivery in Ontario improved adherence but did not find any change in clinical outcomes at 1 year. CRNA affects many Canadians. The estimated percentage depends on the sampling frame, the main predictors tend to be financial, and its association with clinical outcomes in Canada remains unproven.
Tài liệu tham khảo
Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med. 2007;22(6):864–71.
Hennessy DA, Sanmartin C, Ronksley P, Weaver R, Campbell D, Manns B, et al. Out-of-pocket spending on drugs and pharmaceutical products and cost-related prescription non-adherence among Canadians with chronic disease. Ottawa: Statistics Canada; 2016.
Morgan SG, Lee A. Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries. BMJ Open. 2017;7(1):e014287.
Naci H, Soumerai SB, Ross-Degnan D, Zhang F, Briesacher BA, Gurwitz JH, et al. Medication affordability gains following Medicare Part D are eroding among elderly with multiple chronic conditions. Health Affairs. 2014;33(8):1435–43.
Lee M, Salloum RG. Racial and ethnic disparities in cost-related medication non-adherence among cancer survivors. J Cancer Surviv Res Pract. 2016;10(3):534–44.
Harrold LR, Briesacher BA, Peterson D, Beard A, Madden J, Zhang F, et al. Cost-related medication nonadherence in older patients with rheumatoid arthritis. J Rheumatol. 2013;40(2):137–43.
Marcum ZA, Zheng Y, Perera S, Strotmeyer E, Newman AB, Simonsick EM, et al. Prevalence and correlates of self-reported medication non-adherence among older adults with coronary heart disease, diabetes mellitus, and/or hypertension. Res Soc Adm Pharm. 2013;9(6):817–27.
Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. J Am Med Assoc. 2007;298(1):61–9.
Mindaugas S, SJ FJ, Eija V, Gabriella MM, Örjan S, Francisco TG, et al. Factors associated with refraining from buying prescribed medications among older people in Europe. Aust J Ageing. 2014;33(4):E25–30.
Leung VC, Jin YP, Hatch W, Mammo Z, Trope GE, Buys YM, et al. The relationship between sociodemographic factors and persistence with topical glaucoma medications. J Glaucoma. 2015;24(1):69–76.
Levesque A, Li HZ, Pahal JS. Factors related to patients’ adherence to medication and lifestyle change recommendations: data from Canada. Int J Psychol Stud. 2012;4:42.
Lummis HL, Sketris IS, Gubitz GJ, Joffres MR, Flowerdew GJ. Medication persistence rates and factors associated with persistence in patients following stroke: a cohort study. BMC Neurol. 2008;8(no pagination):25.
Gourzoulidis G, Kourlaba G, Stafylas P, Giamouzis G, Parissis J, Maniadakis N. Association between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure. Health Policy. 2017;121(4):363–77.
Mikyas Y, Agodoa I, Yurgin N. A systematic review of osteoporosis medication adherence and osteoporosis-related fracture costs in men. Appl Health Econ Health Policy. 2014;12(3):267–77.
Blanchard J, Madden JM, Ross-Degnan D, Gresenz CR, Soumerai SB. The relationship between emergency department use and cost-related medication nonadherence among Medicare beneficiaries. Ann Emerg Med. 2013;62(5):475–85.
Lieberman DA, Polinski JM, Choudhry NK, Avorn J, Fischer MA. Medicaid prescription limits: policy trends and comparative impact on utilization. BMC Health Serv Res. 2016;16:15.
Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. Br Med J. 2006;333(7557):15–8.
Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521–30.
McGrady ME, Hommel KA. Medication adherence and health care utilization in pediatric chronic illness: a systematic review. Pediatrics. 2013;132(4):730–40.
Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088–97.
Atella V, Schafheutle E, Noyce P, Hassell K. Affordability of medicines and patients’ cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK. Appl Health Econ Health Policy. 2005;4(1):23–35.
Schafheutle EI, Hassell K, Noyce PR, Weiss MC. Access to medicines: cost as an influence on the views and behaviour of patients. Health Soc Care Community. 2002;10(3):187–95.
Davidova J, Ivanovic N, Praznovcova L. Participation in pharmaceutical costs and seniors’ access to medicines in the Czech Republic. Cent Eur J Public Health. 2008;16(1):26–8.
CIHI. National health expenditure trends, 1975 to 2017. www.cihi.ca2017 [cited 2018. Available from: https://www.cihi.ca/sites/default/files/document/nhex2017-trends-report-en.pdf.
Clement F, Memedovich KA. Drug coverage in Canada: gaps and opportunities. J Psychiatry Neurosci. 2018;43(3):148.
Gagnon M-A. The role and impact of cost-sharing mechanisms for prescription drug coverage. CMAJ. 2017;189(19):E680–E1.
Morgan SG, Gagnon M-A, Mintzes B, Lexchin J. A better prescription: advice for a national strategy on pharmaceutical policy in Canada. Healthc Policy. 2016;12(1):18.
Morgan SG, Law M, Daw JR, Abraham L, Martin D. Estimated cost of universal public coverage of prescription drugs in Canada. CMAJ. 2015;187(7):491–7.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W-65–94.
Agarwal A, Guyatt GH, Busse JW. Methods commentary: risk of bias in cross-sectional surveys of attitudes and practices 2017 Available from: https://www.evidencepartners.com/resources/methodological-resources/risk-of-bias-cross-sectional-surveys-of-attitudes-and-practices/.
Critical Appraisal Skills Programme. CASP Checklist: 10 questions to help you make sense of a qualitative research. 2018 cited 2018. Available from: https://casp-uk.net/wp-content/uploads/2018/01/CASP-Qualitative-Checklist.pdf.
Cochrane Effective Practice and Organisation of Care (EPOC). Suggested risk of bias criteria for EPOC reviews. 2017 Available from: https://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources-for-authors2017/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf.
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Summary assessments of risk of bias 2011 Available from: https://handbook-5-1.cochrane.org/index.htm#chapter_8/8_7_summary_assessments_of_risk_of_bias.htm.
Brand FN, Smith RT, Brand PA. Effect of economic barriers to medical care on patients’ noncompliance. Public Health Rep. 1977;92(1):72–8.
Kennedy J, Morgan S. A cross-national study of prescription nonadherence due to cost: data from the joint Canada-United States survey of health. Clin Ther. 2006;28(8):1217–24.
Hirth RA, Greer SL, Albert JM, Young EW, Piette JD. Out-of-pocket spending and medication adherence among dialysis patients in twelve countries. Health Aff. 2008;27(1):89–102.
Kennedy J, Morgan S. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 international health policy survey in seven countries. Clin Ther. 2009;31(1):213–9.
Kemp A, Roughead E, Preen D, Glover J, Semmens J. Determinants of self-reported medicine underuse due to cost: a comparison of seven countries. J Health Serv Res Policy. 2010;15(2):106–14.
Law MR, Cheng L, Dhalla IA, Heard D, Morgan SG. The effect of cost on adherence to prescription medications in Canada. CMAJ. 2012;184(3):297–302.
Zheng B, Poulose A, Fulford M, Holbrook A. A pilot study on cost-related medication nonadherence in Ontario. J Popul Ther Clin Pharmacol. 2012;19(2):e239–e47.
Hunter CE, Palepu A, Farrell S, Gogosis E, O’Brien K, Hwang SW. Barriers to prescription medication adherence among homeless and vulnerably housed adults in three Canadian cities. J Prim Care Community Health. 2015;6(3):154–61.
Lee A, Morgan S. Cost-related nonadherence to prescribed medicines among older Canadians in 2014: a cross-sectional analysis of a telephone survey. CMAJ Open. 2017;5(1):E40–E4.
Sarnak DO, Squires D, Kuzmak G, Bishop S. Paying for prescription drugs around the world: why is the U.S. an outlier? Issue Brief. 2017;2017:1–14.
LJJ S, Adams T, Phipps-Taylor M, Winblad U, Clement F. Is Canadian healthcare affordable? A comparative analysis of the Canadian healthcare system from 2004 to 2014. Healthcare Policy. 2017;13(1):43–58.
Law MR, Cheng L, Kolhatkar A, Goldsmith LJ, Morgan SG, Holbrook AM, et al. The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey. CMAJ Open. 2018;6(1):E63–70.
Laba T-L, Cheng L, Kolhatkar A, Law MR. Cost-related nonadherence to medicines in people with multiple chronic conditions. Res Soc Adm Pharm. 2020;16(3):415–21.
Men F, Gundersen C, Urquia ML, Tarasuk V. Prescription medication nonadherence associated with food insecurity: a population-based cross-sectional study. CMAJ open. 2019;7(3):E590–E7.
Monagle SR, Hirsh J, Bhagirath VC, Ginsberg JS, Bosch J, Kruger P, et al. Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada. J Thromb Thrombolysis. 2018;46(3):310–5.
Yao S, Lix L, Shevchuk Y, Teare G, Blackburn DF. Reduced out-of-pocket costs and medication adherence - a population-based study. J Popul Ther Clin Pharmacol. 2018;25(1):e1–e17.
Dormuth CR, Glynn RJ, Neumann P, Maclure M, Brookhart AM, Schneeweiss S. Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clin Ther. 2006;28(6):964–78.
Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation. 2007;115(16):2128–35.
Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ. Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction. Am J Manag Care. 2007;13(8):445–52.
Goldsmith LJ, Kolhatkar A, Popowich D, Holbrook AM, Morgan SG, Law MR. Understanding the patient experience of cost-related non-adherence to prescription medications through typology development and application. Soc Sci Med. 2017;194:51–9.
Gupta S, McColl MA, Guilcher SJT, Smith K. Managing medication cost burden: a qualitative study exploring experiences of people with disabilities in Canada. Int J Environ Res Public Health. 2019;16(17):3066.
Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. J Am Med Assoc. 2001;285(4):421–9.
Pilote L, Beck C, Richard H, Eisenberg MJ. The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients. CMAJ. 2002;167(3):246–52.
Persaud N, Bedard M, Boozary AS, Glazier RH, Gomes T, Hwang SW, et al. Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN Meds Randomized Clinical Trial. JAMA Intern Med. 2020;180(1):27–34.
Krol BL. The effect of free distribution of essential medicines on adherence by income sources and level. Toronto: University of Toronto; 2019.
Government of Canada. Non-insured health benefits for First Nations and Inuit [Available from: https://www.canada.ca/en/indigenous-services-canada/services/non-insured-health-benefits-first-nations-inuit.html. Accessed 25 Mar 2020.
Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA. 2017;318(14):1377–84.
Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:CD000011.
Wang TY, Kaltenbach LA, Cannon CP, Fonarow GC, Choudhry NK, Henry TD, et al. Effect of medication co-payment vouchers on P2Y12 inhibitor use and major adverse cardiovascular events among patients with myocardial infarction: the ARTEMIS randomized clinical trial effect of co-payment vouchers on antiplatelet adherence and CVD events effect of co-payment vouchers on antiplatelet adherence and CVD events. JAMA. 2019;321(1):44–55.
Canada Go. Towards implementation of National Pharmacare Discussion Paper 2018 [Available from: https://www.canada.ca/content/dam/hc-sc/documents/corporate/publications/council_on_pharmacare_EN.PDF.
Acri K. The unintended consequences of National Pharmacare Programs: the experiences of Australia, New Zealand, and the UK 2018 [Available from: https://www.fraserinstitute.org/studies/unintended-consequences-of-national-pharmacare-programs.